Table 1.
Inflammatory and immune effects of sakuranetin treatment. OVA exposure increased inflammatory cells in blood (cells/mm3), bronchial lavage fluid (BALF 104 cell/mL), IgE, IgG1, IgG2a in serum (OD), and the mass of immune organs (%). ##p < 0.05 and #p < 0.001 compared with SAL; ∗∗p < 0.05 and ∗p < 0.001 compared with OVA; €p < 0.001 compared with SK. Data represent mean ± SEM from 8 to 11 mice per group.
| Data/groups | SAL | OVA | SK | DX |
|---|---|---|---|---|
| Bone marrow × 106 cells/mL | ||||
| Total cells | 38.25 ± 6.90 | 50.64 ± 8.05 | 42.64 ± 8.23 | 37.83 ± 11.48 |
| Blood differential × cells/mm3 | ||||
| Total WBC | 5,290.0 ± 1,327.0 | 8,340.0 ± 1,658.0 | 7,310.0 ± 2,083.0 | 4,913.0 ± 1,339.0 |
| Macrophages | 305.20 ± 70.10 | 837.90 ± 415.60 | 377.40 ± 211.30 | 245.80 ± 185.40 |
| Lymphocytes | 1,752.0 ± 397.30 | 2,685.0 ± 497.50 | 1,339.0 ± 303.30 | ∗∗764.90 ± 321.50 |
| Neutrophils | 3,055.0 ± 947.30 | 2,455.0 ± 613 | 4,665.0 ± 1,196 | 3,852.0 ± 842.90 |
| Eosinophils | 177.90 ± 53.55 | ##2,382.0 ± 706 | ∗∗377.40 ± 211.30 | ∗∗123.60 ± 51.07 |
| BALF × 104 cell/mL | ||||
| Total WBC | 2.18 ± 0.71 | #18.72 ± 7.30 | ∗ ,##7.30 ± 1.35 | ∗3.75 ± 0.76 |
| Macrophages | 1.92 ± 0.56 | #9.44 ± 0.93 | $3.38 ± 0.78 | ∗2.55 ± 0.43 |
| Lymphocytes | 0.20 ± 0.14 | ##1.19 ± 0.25 | 0.74 ± 0.41 | ∗∗0.20 ± 0.09 |
| Neutrophils | 0.05 ± 0.03 | ##0.95 ± 0.29 | 0.75 ± 0.23 | 0.61 ± 0.10 |
| Eosinophils | 0.01 ± 0.004 | #7.12 ± 1.11 | ∗2.42 ± 0.89 | ∗0.39 ± 0.22 |
| OVA-specific antibody (OD) | ||||
| IgE | 0.07 ± 0.032 | ##1.23 ± 0.329 | ∗∗0.47 ± 0.055 | ##1.28 ± 0.45 |
| IgG1 | 1.47 ± 0.317 | 2.08 ± 0.208 | 1.54 ± 0.321 | 2.45 ± 0.01 |
| IgG2a | 0.06 ± 0.008 | ##2.21 ± 0.405 | ##1.91 ± 0.473 | 1.17 ± 0.91 |
| Organs/mice weight (%) | ||||
| Thymus | 0.18 ± 0.01 | ##0.26 ± 0.02 | ∗∗0.15 ± 0.02 | ∗0.11 ± 0.01 |
| Spleen | 0.45 ± 0.04 | ##0.59 ± 0.01 | ∗∗0.49 ± 0.03 | ∗ ,#,€0.24 ± 0.01 |